Researchers found that patients with the chronic inflammatory skin disease exhibit distinct inflammatory patterns later in the day, alongside disruptions in daily immune rhythms that can be partially restored using anti IL 23 therapy.
Evening Inflammation Tied to Psoriasis Severity
Patients with psoriasis demonstrate reduced time-of-day variation in circulating lymphocytes, driven largely by lower evening lymphocyte counts, according to the study. At the same time, these patients exhibit an evening-biased inflammatory profile. This profile features increased levels of cytokines and chemokines involved in inflammation and leukocyte migration. The degree of this daily immune variation directly correlates with disease activity. According to the research, time-of-day-dependent variation in interleukin-31 positively correlates with Psoriasis Area and Severity Index (PASI) scores. Conversely, variation in T helper 17 cells and the CD4-positive to CD8-positive ratio show negative correlations with disease severity. Furthermore, patients who do not respond to treatment display higher pretreatment evening interleukin-31 levels and a more pronounced pro-inflammatory profile than treatment responders.
Anti-IL-23 Therapy Restores Disrupted Immune Rhythms
Anti-IL-23 therapy reduces overall inflammatory mediator levels and partially restores disrupted time-of-day immune dynamics, particularly during the evening hours, according to clinical findings. Publicly available skin transcriptomic datasets analyzed using the ZeitZeiger algorithm demonstrate increased late-time-of-day inflammatory activity and immune cell infiltration within psoriatic skin before treatment. Both of these markers attenuate significantly following biologic administration. Authors of the study suggest that incorporating temporal immune context into biomarker assessments could improve how clinicians interpret inflammatory markers and guide future therapeutic strategies.
Did You Know? Psoriasis is increasingly recognized as a systemic immune-mediated disorder rather than a condition restricted entirely to the skin. According to a review published in Frontiers in Immunology, an estimated 43 million people worldwide were living with psoriasis in 2021, with prevalence varying across global regions.
Systemic Immune Disruption and Comorbidities
The biological scope of psoriasis extends well beyond visible cutaneous plaques. According to findings highlighted in Frontiers in Immunology, persistent immune activation, altered myeloid programming, and dysregulated immunometabolic pathways establish a state of chronic inflammatory priming. Elevated circulating cytokines exert functional effects on vascular endothelium, adipose tissue, and hematopoietic niches, pointing to interconnected inflammatory circuits. Molecular imaging studies using FDG-PET/CT demonstrate increased metabolic activity in hematopoietic organs that parallels vascular inflammation and subclinical atherosclerosis. This evidence supports an integrated cardio-hematopoietic inflammatory axis that explains why disease activity cannot always be gauged by skin involvement alone.
Frequently Asked Questions
Why do psoriasis symptoms often worsen later in the day?
How does anti-IL-23 therapy affect daily immune rhythms?
Anti-IL-23 therapy reduces inflammatory mediator levels and partially restores disrupted time-of-day immune dynamics, particularly during the evening hours, according to clinical findings.
What is the link between interleukin-31 and psoriasis severity?
Time-of-day-dependent variation in interleukin-31 positively correlates with Psoriasis Area and Severity Index (PASI) scores. Non-responders to treatment also show higher pretreatment evening interleukin-31 levels.
Is psoriasis limited only to the skin?
No. According to Frontiers in Immunology, psoriasis is a systemic immune-mediated disorder involving circulating inflammatory mediators, bone marrow activation, vascular inflammation, and metabolic dysregulation.
Stay informed on the latest breakthroughs in dermatology and immunology. Subscribe to our newsletter or explore our comprehensive archive of medical research updates to learn more about managing chronic inflammatory conditions.
Keep reading